Search ↗

Comparison

Glutathione vs MOTS-c

Both are mitochondrial & longevity, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Glutathione is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

Glutathione MOTS-c
Class Mitochondrial & longevity Mitochondrial & longevity
Evidence Clinical trials Preliminary human
Human trials ~25 ~3
Half-life ~10 minutes (intravenous) ~1-2 hours
Reported range 200 mg - 2 g 5-10 mg
Frequency 1-3x weekly (intravenous or intramuscular) 2-3x weekly
Routes Intramuscular, Subcutaneous, Oral Subcutaneous, Intramuscular
FDA approved No No
Research use only No Yes
Banned in sport No No
Studied for Antioxidant support, Hepatic detoxification, Skin brightening Metabolic health research, Insulin sensitivity, Exercise capacity research, Longevity
Reported side effects Injection-site reactions, Transient nausea, Flushing Injection-site reactions, Transient fatigue, Headache

Glutathione

Glutathione is a tripeptide of glutamate, cysteine and glycine, and the dominant thiol antioxidant inside cells. It neutralises reactive oxygen species directly, serves as cofactor for glutathione peroxidases, and is central to phase II hepatic detoxification. Orally administered glutathione is largely hydrolysed in the gut, which is why intravenous and liposomal routes are used, and why cysteine donors such as N-acetylcysteine are often a more practical way to raise intracellular levels.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene rather than in nuclear DNA, which makes it unusual among signalling peptides. It regulates the folate-methionine cycle, leading to accumulation of AICAR and consequent AMPK activation, shifting metabolism toward glucose uptake and fatty acid oxidation. Exercise raises endogenous MOTS-c, and levels fall with age, which is the basis of both the exercise-mimetic framing and the longevity interest. Human trial data is limited.

Glutathione vs MOTS-c: common questions

What is the difference between Glutathione and MOTS-c?

Both are mitochondrial & longevity. Glutathione: The principal endogenous intracellular antioxidant, a tripeptide with poor oral bioavailability. MOTS-c: A mitochondria-encoded peptide that acts as an exercise mimetic through AMPK, and one of the better-characterised mitochondrial-derived peptides.

Which has stronger evidence, Glutathione or MOTS-c?

Glutathione has the stronger evidence base (clinical trials, about 25 human studies) compared with MOTS-c (preliminary human).

Are Glutathione and MOTS-c FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 124886) ↗ · structure, identifiers, synonyms
  2. CAS Registry Number 70-18-8 ↗ · chemical identity
  3. PubChem compound record (CID 146675088) ↗ · structure, identifiers, synonyms
  4. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products

Published literature

  1. Kumar P, Liu C, Suliburk J, et al.. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.J Gerontol A Biol Sci Med Sci 2023.PubMed 35975308 · doi:10.1093/gerona/glac135
  2. Aldini G, Altomare A, Baron G, et al.. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why.Free Radic Res 2018.PubMed 29742938 · doi:10.1080/10715762.2018.1468564
  3. Whalen R, Boyer TD. Human glutathione S-transferases.Semin Liver Dis 1998.PubMed 9875553 · doi:10.1055/s-2007-1007169
  4. Richie JP Jr, Nichenametla S, Neidig W, et al.. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.Eur J Nutr 2015.PubMed 24791752 · doi:10.1007/s00394-014-0706-z
  5. Lapenna D. Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging.Ageing Res Rev 2023.PubMed 37683986 · doi:10.1016/j.arr.2023.102066
  6. Calabrese G, Morgan B, Riemer J. Mitochondrial Glutathione: Regulation and Functions.Antioxid Redox Signal 2017.PubMed 28558477 · doi:10.1089/ars.2017.7121
  7. Duperray J, Sergheraert R, Chalothorn K, et al.. The effects of the oral supplementation of L-Cystine associated with reduced L-Glutathione-GSH on human skin pigmentation: a randomized, double-blinded, benchmark- and placebo-controlled clinical trial.J Cosmet Dermatol 2022.PubMed 33834608 · doi:10.1111/jocd.14137
  8. Fraternale A, Brundu S, Magnani M. Glutathione and glutathione derivatives in immunotherapy.Biol Chem 2017.PubMed 27514076 · doi:10.1515/hsz-2016-0202
  9. Zhang Z, Chen D, Du K, et al.. MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.Mitochondrion 2023.PubMed 37307934 · doi:10.1016/j.mito.2023.06.002
  10. Mohtashami Z, Singh MK, Salimiaghdam N, et al.. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.Int J Mol Sci 2022.PubMed 36233287 · doi:10.3390/ijms231911991
  11. Amado CA, Agüero J, García-Unzueta M, et al.. MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.J Transl Med 2026.PubMed 42243958 · doi:10.1186/s12967-026-08398-2
  12. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.Free Radic Biol Med 2016.PubMed 27216708 · doi:10.1016/j.freeradbiomed.2016.05.015
  13. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.Front Endocrinol (Lausanne) 2023.PubMed 36761202 · doi:10.3389/fendo.2023.1120533
  14. Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence.Rejuvenation Res 2018.PubMed 30058454 · doi:10.1089/rej.2018.2114
  15. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  16. Cuyàs E, Verdura S, Martin-Castillo B, et al.. Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging (Albany NY) 2022.PubMed 36490309 · doi:10.18632/aging.204423

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.